Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BVS5
UPID:
TR61B_HUMAN
Alternative names:
mRNA methyladenosine-N(1)-methyltransferase
Alternative UPACC:
Q9BVS5; Q9H0Q9; Q9NWS7
Background:
The tRNA (adenine(58)-N(1))-methyltransferase, mitochondrial, also known as mRNA methyladenosine-N(1)-methyltransferase, plays a crucial role in mitochondrial function. It catalyzes the formation of N(1)-methyladenine in various tRNAs within the mitochondrion, impacting tRNA(Leu), tRNA(Lys), and tRNA(Ser). This enzyme also modifies mitochondrial 16S ribosomal RNA, essential for mitoribosomal structure and function, and acts on MT-ND5 mRNA, affecting mitochondrial translation.
Therapeutic significance:
Understanding the role of tRNA (adenine(58)-N(1))-methyltransferase, mitochondrial could open doors to potential therapeutic strategies.